Aclaris Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Aclaris Therapeutics

01/08/2025 15:28

Aclaris Therapeutics Inc ACRS.OQ ACRS.O is expected to  show a fall in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2025

The Wayne Pennsylvania-based  company is expected to report a 50.4% decrease in revenue to $1.373 million from $2.77 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Aclaris Therapeutics Inc is for a loss of 13 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Aclaris Therapeutics Inc is $7.00, about 78.1% above its last closing price of $1.53

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.12
-0.12
-0.12
Met
-2.1
Dec. 31 2025
-0.20
-0.22
-1.01
Missed
-362.1
Sep. 30 2024
0.04
-0.01
-0.11
Missed
-1,826.4​
Jun. 30 2024
-0.20
-0.20
-0.15
Beat
26.6
​​Mar. 31 2024
-0.26
-0.29
-0.24
Beat
16
Dec. 31 2023
-0.33
-0.34
-0.02
Beat
94.2​
Sep. 30 2023
-0.47
-0.48
-0.41
Beat
14.6
Jun. 30 2023
-0.44
-0.45
-0.42
Beat
6.7

This summary was machine generated August 1 at 14:28 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)